Japan’s Q4 GDP growth rebounded only moderately after Q3 drop

After Japan had been repeatedly hit by natural disasters in Q3, Q4 GDP growth saw the expected rebound. According to the first print, Japan’s GDP increased by 1.4% qoq annualized (ann.) after the drop by 2.6% qoq ann. in Q3. However, the figures also show that the rebound was not strong enough to make up for the previous quarter’s drop.

Highlights:

  • According to the first print, Japan’s GDP growth rebounded to 1.4% qoq annualized after the drop by 2.6% qoq ann. in Q3, caused by natural disasters.
  • Private consumption and business investment were the main positive drivers, while net exports and the inventory component dragged on growth.
  • Looking ahead, we expect exports to remain lackluster given softening global growth. By contrast, private consumption is likely to accelerate ahead of the planned sales tax hike in October 2019, but to drop thereafter. Support will also come from fiscal policy.
  • We recently revised our growth forecast already down to 0.9% for 2019. Risks are still tilted to the downside. Slowing growth makes it even more difficult for the BoJ to change its monetary policy stance ahead of the sales tax hike.

Download the full publication below

JAPAN’S Q4 GDP GROWTH REBOUNDED ONLY MODERATELY AFTER Q3 DROP

RELATED INSIGHTS

CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
Citywire video-interview with Peter Marber
Watch Peter Marber, fund manager of this global, non-directional, long/short approach to Emerging Markets debt, in a video-interview by Citywire.
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.